The Effect of Acute Angiotensin-Converting Enzyme and Neutral Endopeptidase 24.11 Inhibition on Plasma Extravasation in the Rat
Authors:
- Anthony C. SulpizioASAnthony C. Sulpizio
- Mark A. PullenMPMark A. Pullen
- Richard M. EdwardsRERichard M. Edwards
- David P. BrooksDBDavid P. Brooks
- 1 June 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 309 (3) , 1141-1147
Abstract
The effect of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) inhibition on microvascular plasma leakage (extravasation) was evaluated in a rat model. Progressive inhibition of ACE using captopril caused increased extravasation when lung ACE was inhibited by >55%. In contrast, the selective inhibition of renal NEP by >90% using ecadotril did not increase extravasation. In NEP-inhibited rats, extravasation produced by the ACE inhibitors captopril and lisinopril was markedly enhanced. The dual ACE and NEP inhibitor omapatrilat, at oral doses of 0.03, 0.1, and 0.3 mg/kg, selectively inhibited lung ACE by 19, 61, and 76%, respectively, and did not cause significant extravasation. Doses of 1 and 10 mg/kg omapatrilat, which produced >90% inhibition of ACE and also inhibited renal NEP by 54 and 78%, respectively, significantly increased extravasation. In this model, bradykinin and substance P produced extravasation that could be abolished by the bradykinin 2 (B2) receptor antagonist Hoe 140 (icatibant) or the neurokinin1 (NK1) antagonist CP99994 [(+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine], respectively. Bradykinin induced extravasation was also partially (∼40%) inhibited by CP99994, indicating that a portion of the response involves B2 receptor-mediated release of substance P. In conclusion, this study is the first to relate the degree of ACE and/or NEP inhibition to extravasation liability in the rat model. Our data clearly demonstrate that ACE inhibitor-induced plasma extravasation is enhanced by concomitant inhibition of NEP. In addition, this study provides further evidence for the role for B2 and NK1 receptors in mediating plasma extravasation in the rat.Keywords
This publication has 39 references indexed in Scilit:
- Vasopeptidase InhibitionHypertension, 2003
- Bradykinin and the pathophysiology of angioedemaInternational Immunopharmacology, 2003
- Omapatrilat- the story of Overture and OctaveInternational Journal of Cardiology, 2002
- Physiologic Consequences of Vasopeptidase Inhibition in HumansJournal of the American Society of Nephrology, 2002
- Omapatrilat Versus LisinoprilHypertension, 2001
- Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivoPharmacological Research, 2001
- Neurogenic plasma leakage in mouse airwaysBritish Journal of Pharmacology, 1999
- Differential effects of phosphoramidon and captopril on NK1 receptor-mediated plasma extravasation in the rat tracheaInflammation Research, 1994
- Effect of synthetic tachykinin analogues on airway microvascular leakage in rats and guinea-pigs: evidence for the involvement of NK-1 receptorsJournal of Autonomic Pharmacology, 1991
- Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lungBiochemical Pharmacology, 1971